177 related articles for article (PubMed ID: 22161157)
1. Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.
Hasby EA
Pathol Oncol Res; 2012 Apr; 18(2):509-18. PubMed ID: 22161157
[TBL] [Abstract][Full Text] [Related]
2. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
[TBL] [Abstract][Full Text] [Related]
3. Survivin in ovary tumors.
Plewka D; Jakubiec-Bartnik B; Morek M; Bogunia E; Bienioszek M; Wolski H; Kotrych D; Dziekan K; Seremak-Mrozikiewicz A; Plewka A
Ginekol Pol; 2015 Jul; 86(7):525-30. PubMed ID: 26376531
[TBL] [Abstract][Full Text] [Related]
4. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
5. The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma.
Yigit S; Demir L; Tarhan MO; Cabuk FK; Ellidokuz H; Erten C; Somali I; Dirican A; Cakalagaoglu F
Neoplasma; 2012; 59(5):475-85. PubMed ID: 22668011
[TBL] [Abstract][Full Text] [Related]
6. Expression of Fas and FasL in human serous ovarian epithelial tumors.
van Haaften-Day C; Russell P; Davies S; King NJ; Tattersall MH
Hum Pathol; 2003 Jan; 34(1):74-9. PubMed ID: 12605369
[TBL] [Abstract][Full Text] [Related]
7. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
Byrne JA; Maleki S; Hardy JR; Gloss BS; Murali R; Scurry JP; Fanayan S; Emmanuel C; Hacker NF; Sutherland RL; Defazio A; O'Brien PM
BMC Cancer; 2010 Sep; 10():497. PubMed ID: 20846453
[TBL] [Abstract][Full Text] [Related]
8. CD105/Ki67 coexpression correlates with tumor progression and poor prognosis in epithelial ovarian cancer.
Liu P; Sun YL; Du J; Hou XS; Meng H
Int J Gynecol Cancer; 2012 May; 22(4):586-92. PubMed ID: 22266931
[TBL] [Abstract][Full Text] [Related]
9. Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy.
Tsiatas ML; Gyftaki R; Liacos C; Politi E; Rodolakis A; Dimopoulos MA; Bamias A
Int J Gynecol Cancer; 2009 Nov; 19(8):1329-34. PubMed ID: 20009885
[TBL] [Abstract][Full Text] [Related]
10. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
11. [Expression of survivin in ovarian epithelial carcinoma and its correlation with expression of Fas and FasL].
Ma XY; He FX; Wu SF; Lu YP; Ma D
Ai Zheng; 2004 Feb; 23(2):173-6. PubMed ID: 14960238
[TBL] [Abstract][Full Text] [Related]
12. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors.
Nhokaew W; Kleebkaow P; Chaisuriya N; Kietpeerakool C
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1161-1169. PubMed ID: 31030490
[TBL] [Abstract][Full Text] [Related]
14. Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells.
Meimei L; Peiling L; Baoxin L; Changmin L; Rujin Z; Chunjie H
Med Oncol; 2011 Mar; 28(1):282-9. PubMed ID: 20054719
[TBL] [Abstract][Full Text] [Related]
15. Outcome in serous ovarian cancer is not associated with LATS expression.
Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2737-2749. PubMed ID: 31586262
[TBL] [Abstract][Full Text] [Related]
16. Influence of hypoxia inducible factors on the immune microenvironment in ovarian cancer.
Duechler M; Peczek L; Szubert M; Suzin J
Anticancer Res; 2014 Jun; 34(6):2811-9. PubMed ID: 24922644
[TBL] [Abstract][Full Text] [Related]
17. Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway.
Yousif HMA; Mohammed RAA
Curr Probl Cancer; 2019 Aug; 43(4):377-385. PubMed ID: 30446260
[TBL] [Abstract][Full Text] [Related]
18. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis.
Fang Y; Li Z; Wang X; Zhang S
Tumour Biol; 2012 Dec; 33(6):2299-306. PubMed ID: 22923389
[TBL] [Abstract][Full Text] [Related]
19. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer.
Leffers N; Vermeij R; Hoogeboom BN; Schulze UR; Wolf R; Hamming IE; van der Zee AG; Melief KJ; van der Burg SH; Daemen T; Nijman HW
Int J Cancer; 2012 Jan; 130(1):105-12. PubMed ID: 21328579
[TBL] [Abstract][Full Text] [Related]
20. Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms.
Kanter M; Turan G; Usta C; Usta A; Esen HH; Tavlı L; Celik C; Demirkol Y; Kanter B
J Mol Histol; 2016 Apr; 47(2):145-52. PubMed ID: 26815661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
